应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
06990 科伦博泰生物-B
未开盘 05-07 16:08:17
161.000
-13.000
-7.47%
最高
175.400
最低
160.500
成交量
37.43万
今开
175.400
昨收
174.000
日振幅
8.56%
总市值
352.90亿
流通市值
203.87亿
总股本
2.19亿
成交额
6,151万
换手率
0.30%
流通股本
1.27亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
科伦博泰生物-B一度涨超11%创新高 主要产品获FDA批准2期试验
格隆汇 · 05-06 15:34
科伦博泰生物-B一度涨超11%创新高 主要产品获FDA批准2期试验
科伦博泰生物-B现涨超7% 主要产品A400获美国FDA批准开展2期临床试验
新浪港股 · 05-06 11:23
科伦博泰生物-B现涨超7% 主要产品A400获美国FDA批准开展2期临床试验
港股异动 | 科伦博泰生物-B(06990)涨超6% 主要产品A400获美国FDA批准开展2期临床试验
智通财经 · 05-06 10:06
港股异动 | 科伦博泰生物-B(06990)涨超6% 主要产品A400获美国FDA批准开展2期临床试验
科伦博泰生物-B(06990)上涨5.43%,报172.9元/股
金融界 · 05-06 10:00
科伦博泰生物-B(06990)上涨5.43%,报172.9元/股
科伦博泰生物-B(06990)股价上升5.427%,现价港币$172.9
阿斯达克财经 · 05-06 10:00
科伦博泰生物-B(06990)股价上升5.427%,现价港币$172.9
科伦博泰生物-B:A400项目获得美国FDA批准进入2期临床开发
和讯网 · 05-06 09:10
科伦博泰生物-B:A400项目获得美国FDA批准进入2期临床开发
科伦博泰生物-B:主要产品A400(EP0031)获FDA批准开启2期试验
新浪港股 · 05-06 08:19
科伦博泰生物-B:主要产品A400(EP0031)获FDA批准开启2期试验
科伦博泰生物(06990.HK)主要产品EP0031获FDA批准开发2期试验
阿斯达克财经 · 05-05 21:19
科伦博泰生物(06990.HK)主要产品EP0031获FDA批准开发2期试验
科伦博泰生物-B(06990):主要产品A400(EP0031)获美国食品药品监督管理局批准开启2期试验
智通财经 · 05-03
科伦博泰生物-B(06990):主要产品A400(EP0031)获美国食品药品监督管理局批准开启2期试验
科伦药业、川宁生物、科伦博泰生物构成“品”字型运营平台 总市值再创新高
中国网财经 · 04-30
科伦药业、川宁生物、科伦博泰生物构成“品”字型运营平台 总市值再创新高
科伦博泰生物-B(06990)下跌5.12%,报159.3元/股
金融界 · 04-30
科伦博泰生物-B(06990)下跌5.12%,报159.3元/股
科伦博泰生物-B(06990)股价上升5.179%,现价港币$176.7
阿斯达克财经 · 04-29
科伦博泰生物-B(06990)股价上升5.179%,现价港币$176.7
ADC赛道投资分水岭显现,“错锋竞争+造血研发”成新风向标?
智通财经 · 04-26
ADC赛道投资分水岭显现,“错锋竞争+造血研发”成新风向标?
科伦博泰生物-B(06990)上涨10.33%,报169.8元/股
金融界 · 04-26
科伦博泰生物-B(06990)上涨10.33%,报169.8元/股
科伦博泰生物-B(06990):年报首秀营收增92%,默沙东合作产品7款在研
和讯网 · 04-25
科伦博泰生物-B(06990):年报首秀营收增92%,默沙东合作产品7款在研
港股异动 | 科伦博泰生物-B(06990)涨超6% 背靠默沙东23年营收大涨 SKB264有望成泛癌种显著获益的ADC大单品
智通财经 · 04-25
港股异动 | 科伦博泰生物-B(06990)涨超6% 背靠默沙东23年营收大涨 SKB264有望成泛癌种显著获益的ADC大单品
科伦博泰生物-B(06990)上涨5.26%,报162.1元/股
金融界 · 04-25
科伦博泰生物-B(06990)上涨5.26%,报162.1元/股
港股异动 | 科伦博泰生物-B(06990)再涨超6% SKB-264肺癌数据亮眼 海内外取得多项关键进展
智通财经 · 04-23
港股异动 | 科伦博泰生物-B(06990)再涨超6% SKB-264肺癌数据亮眼 海内外取得多项关键进展
科伦博泰生物-B04月22日主力资金流出88万元 连续3日减仓
自选股智能写手 · 04-22
科伦博泰生物-B04月22日主力资金流出88万元 连续3日减仓
科伦博泰生物-B(06990.HK):SKB264国际化进程加速
广发证券 · 04-19
科伦博泰生物-B(06990.HK):SKB264国际化进程加速
加载更多
公司概况
公司名称:
科伦博泰生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。该公司主要从事生物药品、化学药品原料、化学药品制剂的研发、生产和销售。该公司的产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。
发行价格:
--
{"stockData":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":161,"timestamp":1715069297019,"preClose":174,"halted":0,"volume":374300,"delay":0,"floatShares":126624405,"shares":219195499,"eps":-3.078506,"marketStatus":"未开盘","marketStatusCode":0,"change":-13,"latestTime":"05-07 16:08:17","open":175.4,"high":175.4,"low":160.5,"amount":61510121,"amplitude":0.085632,"askPrice":161.1,"askSize":600,"bidPrice":161,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":-3.0785059105458292,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1715131800000},"adr":0,"listingDate":1689004800000,"adjPreClose":174,"openAndCloseTimeList":[[1715045400000,1715054400000],[1715058000000,1715068800000]],"volumeRatio":1.7955035188683546,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06990","defaultTab":"news","newsList":[{"id":"2433414071","title":"科伦博泰生物-B一度涨超11%创新高 主要产品获FDA批准2期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2433414071","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2433414071?lang=zh_cn&edition=full","pubTime":"2024-05-06 15:34","pubTimestamp":1714980883,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(6990.HK)午后一度涨超11%,高见182.2港元刷新上市高价,总市值近400亿港元。该公司的主要产品A400(EP0031)(在转染过程中重排(RET)小分子激酶抑制剂项目,亦称为KL590586或EP0031)获得了美国食品药品监督管理局(FDA)批准进入2期临床开发。A400(EP0031)是第二代选择性RET抑制剂(SRI),对常见的RET基因融合和突变具有广泛活性。\n\n\r\n 责任编辑:山上","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/06153440528022.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433493047","title":"科伦博泰生物-B现涨超7% 主要产品A400获美国FDA批准开展2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2433493047","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2433493047?lang=zh_cn&edition=full","pubTime":"2024-05-06 11:23","pubTimestamp":1714965808,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990)早盘上涨7.20%,现报175.80港元,成交额1951.98万港元。\n 科伦博泰生物公布,其主要产品A400(EP0031)(在转染过程中重排(RET)小分子激酶抑制剂项目,亦称为KL590586或EP0031获美国食品药品监督管理局(FDA)批准进入2期临床开发。据悉,A400(EP0031)是第二代选择性RET抑制剂(SRI),对常见的RET基因融合和突变具有广泛活性。\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-06/doc-inauhfhz3259883.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-05-06/doc-inauhfhz3259883.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433464776","title":"港股异动 | 科伦博泰生物-B(06990)涨超6% 主要产品A400获美国FDA批准开展2期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2433464776","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433464776?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:06","pubTimestamp":1714961177,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科伦博泰生物-B涨超6%,截至发稿,涨6.46%,报174.6港元,成交额1430.41万港元。消息面上,科伦博泰生物公布,其主要产品A400(在转染过程中重排(RET)小分子激酶抑制剂项目,亦称为KL590586或EP0031获美国食品药品监督管理局(FDA)批准进入2期临床开发。据悉,A400是第二代选择性RET抑制剂,对常见的RET基因融合和突变具有广泛活性。瑞银此前提高对公司SKB264、SKB315和A400 的销售高峰预测,以反映研发进展,并认为SKB264、SKB315和A400在美国进展顺利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117358.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2433462566","title":"科伦博泰生物-B(06990)上涨5.43%,报172.9元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2433462566","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2433462566?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:00","pubTimestamp":1714960853,"startTime":"0","endTime":"0","summary":"5月6日,科伦博泰生物-B(06990)盘中上涨5.43%,截至10:00,报172.9元/股,成交1022.14万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/05/06100040523142.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433462526","title":"科伦博泰生物-B(06990)股价上升5.427%,现价港币$172.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2433462526","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2433462526?lang=zh_cn&edition=full","pubTime":"2024-05-06 10:00","pubTimestamp":1714960800,"startTime":"0","endTime":"0","summary":"[上升股]科伦博泰生物-B(06990) 股价在上午10:00比前收市价上升5.427%,现股价为港币$172.9。至目前为止,今日最高价为$172.9,而最低价为$167.5。总成交量为6.07万股,总成交金额为港币$1.022千万。","market":"other","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180416150419953_s.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240506674/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2433464086","title":"科伦博泰生物-B:A400项目获得美国FDA批准进入2期临床开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2433464086","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2433464086?lang=zh_cn&edition=full","pubTime":"2024-05-06 09:10","pubTimestamp":1714957845,"startTime":"0","endTime":"0","summary":"快讯正文科伦博泰生物-B公司获得美国食品药品监督管理局批准,其主要产品A400小分子激酶抑制剂项目正式进入2期临床试验阶段。科伦博泰生物-B的产品A400是一种第二代选择性RET抑制剂,针对常见的RET基因融合和突变具有广泛的活性。美国FDA的批准是该公司产品开发的重要里程碑,有助于公司进一步验证产品的有效性和安全性。科伦博泰生物-B计划在美国和中国同时开展2期临床试验,预计2025年完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050610050787d65f3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050610050787d65f3b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433346862","title":"科伦博泰生物-B:主要产品A400(EP0031)获FDA批准开启2期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2433346862","media":"新浪港股","top":-1,"share":"https://www.laohu8.com/m/news/2433346862?lang=zh_cn&edition=full","pubTime":"2024-05-06 08:19","pubTimestamp":1714954768,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990)发布公告,该公司的主要产品A400(EP0031)(在转染过程中重排(RET)小分子激酶抑制剂项目,亦称为KL590586或EP0031)获得了美国食品药品监督管理局(FDA)批准进入2期临床开发。\n A400(EP0031)是第二代选择性RET抑制剂(SRI),对常见的RET基因融合和突变具有广泛活性。\n\n股市回暖,抄底炒股先开户!智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读,尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-06/doc-inaufyzc3314835.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-05-06/doc-inaufyzc3314835.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433643802","title":"科伦博泰生物(06990.HK)主要产品EP0031获FDA批准开发2期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2433643802","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2433643802?lang=zh_cn&edition=full","pubTime":"2024-05-05 21:19","pubTimestamp":1714915140,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990.HK) 公布,主要产品A400(EP0031)获得美国食品药品监督管理局(FDA)批准进入2期临床开发。A400是第二代选择性RET(在转染过程中重排)抑制剂,对常见的RET基因融合和突变具有广泛活性。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-05-03 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1347321/latest-news/AAFN","is_publish_highlight":false,"gpt_icon":0},{"id":"2432906693","title":"科伦博泰生物-B(06990):主要产品A400(EP0031)获美国食品药品监督管理局批准开启2期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2432906693","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2432906693?lang=zh_cn&edition=full","pubTime":"2024-05-03 22:24","pubTimestamp":1714746272,"startTime":"0","endTime":"0","summary":"智通财经APP讯,科伦博泰生物-B 发布公告,该公司的主要产品A400获得了美国食品药品监督管理局批准进入2期临床开发。A400是第二代选择性RET抑制剂,对常见的RET基因融合和突变具有广泛活性。于2022年6月,A400已获得FDA批准的新药临床研究申请,进行一项针对RET基因改变的恶性肿瘤患者的1/2期试验。于2023年11月,A400获FDA授予孤儿药资格认定,用于治疗RET融合阳性实体瘤。A400在动物模型中也表现出良好的血脑屏障穿透性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117171.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431493351","title":"科伦药业、川宁生物、科伦博泰生物构成“品”字型运营平台 总市值再创新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2431493351","media":"中国网财经","top":-1,"share":"https://www.laohu8.com/m/news/2431493351?lang=zh_cn&edition=full","pubTime":"2024-04-30 13:57","pubTimestamp":1714456620,"startTime":"0","endTime":"0","summary":"中国网财经4月30日讯 今日,截至午市收盘,川宁生物20%涨停,由科伦药业、川宁生物、科伦博泰生物构成的“品”字型架构运营平台总市值再创新高。截至今日午市收盘,科伦药业、川宁生物、科伦博泰生物三家公司总市值已超1100亿元。据了解,近年来,科伦药业在大输液、抗生素、创新研发等领域高效推进,“品”字型架构运营平台呈现出共振增长的趋势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043014162887c26854&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043014162887c26854&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431387091","title":"科伦博泰生物-B(06990)下跌5.12%,报159.3元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431387091","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2431387091?lang=zh_cn&edition=full","pubTime":"2024-04-30 11:19","pubTimestamp":1714447161,"startTime":"0","endTime":"0","summary":"4月30日,科伦博泰生物-B(06990)盘中下跌5.12%,截至11:19,报159.3元/股,成交2816.85万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/30111940488017.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431047165","title":"科伦博泰生物-B(06990)股价上升5.179%,现价港币$176.7","url":"https://stock-news.laohu8.com/highlight/detail?id=2431047165","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2431047165?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:45","pubTimestamp":1714355100,"startTime":"0","endTime":"0","summary":"[上升股]科伦博泰生物-B(06990) 股价在上午09:45比前收市价上升5.179%,现股价为港币$176.7。至目前为止,今日最高价为$176.7,而最低价为$163.6。总成交量为3.64万股,总成交金额为港币$624.061万。","market":"fut","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20180725133914771_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR240429695/aamm-all-category","is_publish_highlight":false,"gpt_icon":0},{"id":"2430241913","title":"ADC赛道投资分水岭显现,“错锋竞争+造血研发”成新风向标?","url":"https://stock-news.laohu8.com/highlight/detail?id=2430241913","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430241913?lang=zh_cn&edition=full","pubTime":"2024-04-26 16:18","pubTimestamp":1714119495,"startTime":"0","endTime":"0","summary":"今年4月3日,丹麦药企Genmab宣布将以18亿美元全现金交易形式收购一家中国本土的ADC药物研发Biotech普方生物,从而获得其自主研发的ADC技术资产。此前国金证券公布的一份研报也显示,国内ADC在研药物有超过60个是靶向HER2,位居首位。但在强调差异化的ADC赛道,聚集成熟靶点并非一件好事,随着市场竞争趋于白热化,研发企业能否从有限的适应症市场分得一杯羹成为一个未知数,也影响市场对公司后续价值的判断。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1111461.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430457592","title":"科伦博泰生物-B(06990)上涨10.33%,报169.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430457592","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430457592?lang=zh_cn&edition=full","pubTime":"2024-04-26 15:32","pubTimestamp":1714116745,"startTime":"0","endTime":"0","summary":"4月26日,科伦博泰生物-B(06990)盘中上涨10.33%,截至15:32,报169.8元/股,成交7427.3万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/26153240428189.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2430442878","title":"科伦博泰生物-B(06990):年报首秀营收增92%,默沙东合作产品7款在研","url":"https://stock-news.laohu8.com/highlight/detail?id=2430442878","media":"和讯网","top":-1,"share":"https://www.laohu8.com/m/news/2430442878?lang=zh_cn&edition=full","pubTime":"2024-04-25 12:31","pubTimestamp":1714019460,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B 在业绩上也展现出显著的进步。此外,调整后年内亏损额降至4.51亿元,同比减少了24.4%。值得注意的是,科伦博泰生物-B 与制药巨头默沙东的合作进展顺利,已有7款产品处于合作进程中。2023年,公司从默沙东处获得了首付款及里程碑款项,总额达14.21亿元,占公司年内营收的92.27%。据国联证券分析,科伦博泰生物-B 目前在国内外的临床试验布局均取得了显著进展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251311318b51838a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404251311318b51838a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2430417534","title":"港股异动 | 科伦博泰生物-B(06990)涨超6% 背靠默沙东23年营收大涨 SKB264有望成泛癌种显著获益的ADC大单品","url":"https://stock-news.laohu8.com/highlight/detail?id=2430417534","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2430417534?lang=zh_cn&edition=full","pubTime":"2024-04-25 10:11","pubTimestamp":1714011099,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科伦博泰生物-B涨超6%,截止发稿涨6.04%,报163.3港元,成交额2002万港元。业绩方面,3月25日公司发布了上市以来的首份年报。据悉目前科伦博泰与默沙东共有7款处于合作进程中的产品。基于上述合作,2023年,科伦博泰共从默沙东处获取了14.21亿元的首付款及里程碑款项,占公司年内营收的92.27%。此外,科伦博泰SKB264目前正在全球范围内开展针对多个瘤种的单药/联用的Ⅱ期和Ⅲ期临床试验,有望成为泛癌种显著获益的ADC大单品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1109521.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430414263","title":"科伦博泰生物-B(06990)上涨5.26%,报162.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2430414263","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2430414263?lang=zh_cn&edition=full","pubTime":"2024-04-25 09:43","pubTimestamp":1714009434,"startTime":"0","endTime":"0","summary":"4月25日,科伦博泰生物-B(06990)盘中上涨5.26%,截至09:43,报162.1元/股,成交917.41万元。四川科伦博泰生物医药股份有限公司是一家专注于创新药物研发、制造及商业化的生物医药公司,主要致力于内部开发差异化的治疗方法,以支持提高现有的医疗健康水平。公司已建立涵盖全部主要药物开发功能的一体化能力,能够战略性地快速推进33款差异化且具有临床价值的资产管线,其中14款处于临床阶段,并已签署了九项对外许可协议,前期及里程碑付款合共高达118亿美元。截至2023年年报,科伦博泰生物-B营业总收入15.4亿元、净利润-5.74亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/04/25094340399100.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429553821","title":"港股异动 | 科伦博泰生物-B(06990)再涨超6% SKB-264肺癌数据亮眼 海内外取得多项关键进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2429553821","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2429553821?lang=zh_cn&edition=full","pubTime":"2024-04-23 14:22","pubTimestamp":1713853342,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,科伦博泰生物-B再涨超6%,截至发稿,涨6.09%,报148港元,成交额2985.15万港元。消息面上,国联证券指出,2024年AACR会议上,科伦博泰展示的SKB-264肺癌数据亮眼,展现泛瘤种治疗潜力。科伦博泰SKB264目前正在全球范围内开展针对多个瘤种的单药/联用的Ⅱ期和Ⅲ期临床试验,有望成为泛癌种显著获益的ADC大单品。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1107402.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429914549","title":"科伦博泰生物-B04月22日主力资金流出88万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2429914549","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2429914549?lang=zh_cn&edition=full","pubTime":"2024-04-22 16:16","pubTimestamp":1713773808,"startTime":"0","endTime":"0","summary":"04月22日, 科伦博泰生物-B股价涨2.27%,报收139.50元,成交金额4046万元,换手率0.23%,振幅9.46%,量比1.33。科伦博泰生物-B今日主力资金净流出88万元,连续3日净流出,上一交易日主力净流出371万元,今日环比减少76.28%。近一年数据显示,该股主力连续3日净流出后,次日下跌概率为33.33%,平均跌幅为7.48%。该股近5个交易日下跌1.06%,主力资金累计净流出684万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出4289万元,其中净流出天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221617288b45374b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404221617288b45374b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2428871286","title":"科伦博泰生物-B(06990.HK):SKB264国际化进程加速","url":"https://stock-news.laohu8.com/highlight/detail?id=2428871286","media":"广发证券","top":-1,"share":"https://www.laohu8.com/m/news/2428871286?lang=zh_cn&edition=full","pubTime":"2024-04-19 16:21","pubTimestamp":1713514906,"startTime":"0","endTime":"0","summary":"里程碑款兑现,亏损同比收窄。SKB264 国际化加速,默沙东密集开展6 项全球III 期。ADC 平台持续升级,更多新型ADC 进入临床。根据公司2023 年度业绩公告,A166 已在国内申报NDA 治疗HER2+ BC;SKB315 处于全球I/II 期;SKB410 处于I 期;SKB501 的 IND 获得CDE 受理。多项非ADC 资产布局肿瘤自免领域。根据公司2023 年度业绩公告,A167 完成一线治疗鼻咽癌III 期入组;A140 治疗RAS 野生型头颈鳞癌NDA 获CDE 受理;A400 治疗RET+ NSCLC 处于关键临床;SKB378、SKB336 都已完成I 期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191621488b3a237d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404191621488b3a237d&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://kelun-biotech.com","stockEarnings":[{"period":"1week","weight":-0.0434},{"period":"1month","weight":0.1641},{"period":"3month","weight":0.8919},{"period":"6month","weight":0.809},{"period":"1year","weight":1.6568},{"period":"ytd","weight":0.5646}],"compareEarnings":[{"period":"1week","weight":0.0403},{"period":"1month","weight":0.105},{"period":"3month","weight":0.1491},{"period":"6month","weight":0.0553},{"period":"1year","weight":-0.0896},{"period":"ytd","weight":0.084}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。该公司主要从事生物药品、化学药品原料、化学药品制剂的研发、生产和销售。该公司的产品主要用于乳腺癌、非小细胞肺癌、胃肠道癌等非肿瘤疾病的治疗。","exchange":"SEHK","name":"科伦博泰生物-B","nameEN":"SKB BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科伦博泰生物-B,06990,科伦博泰生物-B股票,科伦博泰生物-B股票老虎,科伦博泰生物-B股票老虎国际,科伦博泰生物-B行情,科伦博泰生物-B股票行情,科伦博泰生物-B股价,科伦博泰生物-B股市,科伦博泰生物-B股票价格,科伦博泰生物-B股票交易,科伦博泰生物-B股票购买,科伦博泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科伦博泰生物-B(06990)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科伦博泰生物-B(06990)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}